Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 228

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 228
---
 capital in the future. Future R&D expenses may vary significantly between periods and from current expectations based
on factors such as:

| ● | expenses incurred to conduct                                                     
 preclinical studies required to advance product candidates into clinical trials; |

| ● | per patient clinical trial                                                                                                          
 costs based on a number of factors, including number of patient clinical visits, clinical laboratory testing, and potential medical 
 imaging;                                                                                                                            |

| ● | the number of clinical                                                                                                             
 trials required for approval, the number of patients who enroll in each clinical trial, and the number and geographic locations of 
 sites included in the clinical trials;                                                                                             |

| ● | the length of time required                                                                                     
 to screen and enroll eligible patients, screen-failure rate, or the discontinuation rates of enrolled patients; |

| ● | potential additional safety                  
 monitoring requested by regulatory agencies; |

| ● | the cost of insurance,                                                         
 including product liability insurance, in connection with clinical trials; and |

| ● | suspension or termination                                                                                                               
 of clinical development activities by regulators or institutional review boards for various reasons, including regulatory noncompliance 
 or a finding that the participants are being exposed to unacceptable health risks.                                                      |

General and Administrative Expenses

General and administrative
expenses consist principally of salaries and related costs for personnel in executive and administrative functions, including stock-based
compensation, travel expenses and recruiting expenses. Other general and administrative expenses include professional fees for legal,
accounting and tax-related services and insurance costs.

The Company anticipates
that its general and administrative expenses will increase in the future as the Company increases headcount and contracted services for
operational support for expanded operations and infrastructure. The Company also anticipates that general and administrative expenses
will increase as a result of expenses for accounting, audit, legal and consulting services, as well as costs associated with maintaining
compliance with Nasdaq listing rules and SEC requirements, director and officer liability insurance, investor and public relations activities
and other expenses associated with operating as a public company.

Interest and Other Income, Net

Interest and other income,
net consists predominantly of interest income from interest bearing bank accounts, interest expense on payables, and the gain or loss
on the revaluation of derivative liabilities, which represents the change in fair value of earnout liabilities or outstanding warrants
between periods.

<div align='center'>133</div>

Results of Operations for the three-months ended September 30, 2024 and 2023

<div align='center'>CERO THERAPEUTICS